目的　探讨采用双环乳晕切口在多中心乳腺良性肿瘤临床外科手术中的应用优势。   方法　回顾性分析我院肿瘤外科2016年1月-2017年7月收治的45例行“双环乳晕切口”治疗的“多中心乳腺良性肿瘤”的患者。对所有患者的临床病理因素、手术时间、术中出血量、术后拔管时间、并发症以及术后3个月美容效果、6个月后复发率进行评价。   结果　切除肿瘤数量单侧（5±1）个（2~8个），双侧（8±2）个（3~13个）。肿瘤长径单侧（5.3±1.3）cm（1.5~8.5 cm），双侧（3.0±1.5）cm（1.2~6.5 cm）。术中出血量单侧(8.0±2.8)ml（5~15 ml），双侧(15.4±3.1)ml（10~25 ml）。术后3个月通过门诊和微信随访美容效果，患者满意度在93.3%。术后6个月有37例患者进行彩超复查，其中单侧病变患者22例，复发3例，复发率13.6%；双侧病变患者15例，复发2例，复发率13.3%。   结论　双环乳晕切口在处理分布在不同象限多发性肿瘤、以及有塑形需求的患者人群中具有一定优势。手术安全性高，操作方便，适合临床推广应用。

Objective　Investigating the advantages of using double ring areola incision in the clinical operation of multi-center benign breast tumors.　Methods　A retrospective analysis of 45 cases of multic-enter breast benign tumor treated with double ring areola incision in our department of oncology surgery from January 2016 to July 2017 was conducted. The clinical and pathological factors, operative time, intraoperative blood loss, extubation time, complications and cosmetic result after 3 months, the recurrence rate after 6 months were evaluated.　Result　The number of resected tumor in unilateral sidewas 5±1 (2~8), in bilateral sides was 8±2 (3~13). Tumor size in unilateral side was(5.3±1.3) cm (1.5~8.5 cm), in bilateral sides was(3±1.5) cm (1.2~6.5 cm). The amount of intraoperative bleeding in unilateral was(8±2.8) ml (5~15ml), in bilateral sides was(15.4±3.1)ml (10~25 ml). Cosmetic results were followed up by outpatient and WeChat after 3 months and patients’ satisfaction reached 93.3%. After 6 months, there were 37 patients who underwent Doppler ultrasound examination, including 22 cases of patients with unilateral lesions, in whichtumor in 3 cases of recurred, the recurrence rate in 13.6%; 15 cases of patients with bilateral lesions, in which tumor in 2 cases of recurred, the recurrence rate being 13.3%.　Conclusion　Double ring areola incision has certain advantages in the treatment of patient who has multiple tumors distributed in different quadrants or has shaping demand. The operation is safe and convenient, and suitable for clinical application.